Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.

The cause of a rare, inherited, often fatal kidney disease in many patients remained elusive for years, despite multiple attempts to solve the mystery. Then in 2012, a team of researchers cracked some of the unsolved cases in just six weeks.

Making clinical tools from basic research knowledge is a practice Novartis and FMI researchers pursue. Read how they want to help retinitis pigmentosa patients to see the light.

Speaking with Ganesh Prasanna, Director of Ophthalmology at NIBR.

Jean Silveri shares key insights from her legal career.